Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO ...

Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA. Click here to find ...